APG Asset Management US Inc. Has $4.91 Million Holdings in The Cooper Companies, Inc. (NASDAQ:COO)

APG Asset Management US Inc. increased its position in The Cooper Companies, Inc. (NASDAQ:COO) by 2.4% during the 2nd quarter, HoldingsChannel.com reports. The fund owned 56,841 shares of the medical device company’s stock after buying an additional 1,357 shares during the period. APG Asset Management US Inc.’s holdings in Cooper Companies were worth $4,910,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also recently bought and sold shares of COO. Benjamin F. Edwards & Company Inc. boosted its position in shares of Cooper Companies by 248.6% in the first quarter. Benjamin F. Edwards & Company Inc. now owns 244 shares of the medical device company’s stock valued at $25,000 after acquiring an additional 174 shares during the period. Brown Brothers Harriman & Co. boosted its holdings in Cooper Companies by 412.2% in the 4th quarter. Brown Brothers Harriman & Co. now owns 251 shares of the medical device company’s stock valued at $95,000 after purchasing an additional 202 shares during the period. Covestor Ltd grew its position in Cooper Companies by 305.9% in the 1st quarter. Covestor Ltd now owns 276 shares of the medical device company’s stock worth $28,000 after purchasing an additional 208 shares during the last quarter. Innealta Capital LLC bought a new position in shares of Cooper Companies during the 2nd quarter worth about $25,000. Finally, Crewe Advisors LLC increased its holdings in shares of Cooper Companies by 286.4% during the 2nd quarter. Crewe Advisors LLC now owns 340 shares of the medical device company’s stock worth $30,000 after purchasing an additional 252 shares during the period. Institutional investors and hedge funds own 24.39% of the company’s stock.

Insider Buying and Selling

In other Cooper Companies news, COO Daniel G. Mcbride sold 114,992 shares of Cooper Companies stock in a transaction on Wednesday, September 4th. The stock was sold at an average price of $105.48, for a total value of $12,129,356.16. Following the completion of the transaction, the chief operating officer now owns 44,696 shares in the company, valued at approximately $4,714,534.08. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In other news, CAO Agostino Ricupati sold 1,601 shares of the company’s stock in a transaction that occurred on Tuesday, September 10th. The shares were sold at an average price of $108.03, for a total transaction of $172,956.03. Following the transaction, the chief accounting officer now directly owns 4,818 shares in the company, valued at $520,488.54. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Daniel G. Mcbride sold 114,992 shares of the stock in a transaction that occurred on Wednesday, September 4th. The shares were sold at an average price of $105.48, for a total transaction of $12,129,356.16. Following the sale, the chief operating officer now directly owns 44,696 shares in the company, valued at $4,714,534.08. The disclosure for this sale can be found here. Insiders have sold a total of 256,373 shares of company stock worth $27,637,427 in the last three months. Insiders own 2.00% of the company’s stock.

Cooper Companies Stock Up 1.0 %

Shares of NASDAQ:COO opened at $109.54 on Friday. The company’s fifty day moving average is $99.46 and its 200-day moving average is $95.75. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.18 and a current ratio of 1.99. The Cooper Companies, Inc. has a 52 week low of $75.93 and a 52 week high of $112.38. The company has a market capitalization of $21.82 billion, a PE ratio of 64.34, a P/E/G ratio of 2.63 and a beta of 0.98.

Cooper Companies (NASDAQ:COO) last released its quarterly earnings results on Wednesday, August 28th. The medical device company reported $0.96 EPS for the quarter, beating analysts’ consensus estimates of $0.91 by $0.05. The firm had revenue of $1 billion for the quarter, compared to analyst estimates of $997.30 million. Cooper Companies had a net margin of 9.45% and a return on equity of 9.08%. The company’s revenue for the quarter was up 7.8% compared to the same quarter last year. During the same period in the previous year, the business earned $0.84 earnings per share. Equities research analysts predict that The Cooper Companies, Inc. will post 3.65 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

COO has been the subject of several research reports. Robert W. Baird increased their target price on shares of Cooper Companies from $118.00 to $125.00 and gave the company an “outperform” rating in a research note on Thursday, August 29th. Needham & Company LLC reiterated a “hold” rating on shares of Cooper Companies in a research report on Thursday, August 29th. Piper Sandler boosted their price objective on Cooper Companies from $115.00 to $120.00 and gave the company an “overweight” rating in a research report on Thursday, August 29th. Jefferies Financial Group raised Cooper Companies from a “hold” rating to a “buy” rating and raised their target price for the stock from $107.00 to $115.00 in a research report on Tuesday, July 16th. Finally, Morgan Stanley boosted their price target on shares of Cooper Companies from $95.00 to $104.00 and gave the company an “equal weight” rating in a report on Tuesday, September 10th. Four investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $115.00.

Cooper Companies Company Profile

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.